Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Clinical Trial of TEV-56286 in Healthy Male Participants
NCT06627231Phase 1Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emrusolmin, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Cumulative Amount of Total Radioactivity, Cumulative Percent of TRA From the Total Radioactive Dose Administered and 6 more. Started Oct 2024; status: completed.
02
Drugs
emrusolmin
Beyond the preview
Go deeper on NCT06627231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627231.